logo
Top Analyst Amit Daryanani Sets Expectations on Apple Stock Ahead of WWDC 2025

Top Analyst Amit Daryanani Sets Expectations on Apple Stock Ahead of WWDC 2025

Apple (NASDAQ:AAPL) has frequently ranked among the world's two most valuable companies, but it has now slipped to third place as the tech giant faces pressure from multiple fronts, all of which are dampening investor sentiment.
Confident Investing Starts Here:
The stock has shed 19% this year, dragged down by concerns over antitrust investigations, tariffs, competition in China, and its positioning in AI. The decline makes Apple the weakest performer among the Mag 7 tech giants and puts it well behind the S&P 500, which has gained 1.5% in 2025.
So, with WWDC 2025 (June 9–13) on the horizon, will Apple make a push to close the gap with its big tech peers? Not quite, says Evercore's Amit Daryanani, an analyst ranked in the top 4% of Wall Street stock experts.
Daryanani thinks that compared to previous years, which featured bigger announcements like Apple Intelligence in 2024 and Vision Pro in 2023, expectations are 'rightfully tempered.'
Daryanani reckons the biggest announcement will likely be Apple making its foundation models available to app developers, enabling them to use on-device AI. Additionally, Apple might reveal new partner options beyond OpenAI for its Apple Intelligence platform, which will be built directly into iOS – with Perplexity and Gemini seen as likely candidates. The company is also planning a more extensive update to its operating systems than usual, along with a new naming convention that adds the year at the end, such as iOS 26.
Another key announcement is expected to be a centralized gaming app that will come preinstalled on devices – a strategic move, given that gaming makes up around half of App Store revenue. While there could be a few smaller AI-related updates as well, they likely won't be significant enough to shift the prevailing view that Apple is still trailing behind in the AI space.
But that take is not quite on the money, says Daryanani. 'We continue to think this narrative underestimates Apple's strategy, which is to focus on smaller scale on-device models and efficient large scale models while sitting out on the AI capex arms race,' the 5-star analyst opined.
Rather than trying to match its peers by pouring tens or even hundreds of billions into AI infrastructure, Apple is sticking with a 'more capital light model.' The plan is to let other model providers do the heavy lifting, then charge them – either through revenue sharing or subscription fees – for access to Apple's iOS user base. Daryanani thinks this strategy gives Apple a way to potentially earn strong returns from AI while avoiding the financial risk of investing billions without a 'clear path to monetization.'
'Net/net,' Daryanani summed up, 'We think WWDC will be more low key this year with no hardware announcements or major overhauls on par with last year's Apple Intelligence. Instead we will see some incremental improvements with more meaningful updates expected in 2026.'
All told, Daryanani assigns an Outperform (i.e., Buy) rating to Apple shares, along with a $250 price target that implies a one-year upside of 23%. (To watch Daryanani's track record, click here)
16 other analysts join Daryanani in the AAPL bull camp and with an additional 9 Holds and 4 Sells, the stock claims a Moderate Buy consensus rating. The average price target stands at $228.79, a figure that factors in 12-month returns of ~13%. (See AAPL stock forecast)
To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

An OpenAI exec says she was diagnosed with breast cancer and that ChatGPT has helped her navigate it
An OpenAI exec says she was diagnosed with breast cancer and that ChatGPT has helped her navigate it

Business Insider

time13 minutes ago

  • Business Insider

An OpenAI exec says she was diagnosed with breast cancer and that ChatGPT has helped her navigate it

Kate Rouch, the chief marketing officer at OpenAI, shared on Friday that she was diagnosed with invasive breast cancer weeks after assuming the role, which she called her "dream job," in December. In a thread posted on X, Rouch said she was sharing her story to help other women, adding, "We can't control what happens to us--but we can choose how we face it. My biggest lesson: no one fights alone." Prior to joining OpenAI as the company's first CMO, Rouch was CMO at Coinbase and, before that, spent over a decade at Meta, including as vice president, global head of brand and product marketing. Rouch said she started treatment right around the Super Bowl in February, when OpenAI aired its first-ever ad, and that she has since gone through 13 rounds of chemotherapy while leading OpenAI's marketing team. She wrote that she is expected to make a full recovery. "It has been the hardest season of life — for me, for my husband, and for our two young children," Rouch said, adding she has been supported by OpenAI "at every step." "Silicon Valley can be brutal and transactional. And yet — I've never felt more held," she said, adding that "people showed up in incredible and unexpected ways." Rouch also said OpenAI's ChatGPT has helped her navigate her diagnosis and treatment, including by explaining cancer in a way that is age-appropriate for her kids, helping her manage the side effects of chemo, and creating custom meditations. "Experiencing our work as a patient has made OpenAI's mission feel more personal and important," she said. Rouch said she was sharing her story to encourage other women to "prioritize their health over the demands of families and jobs." "A routine exam saved my life. It could save yours, too," she said. Business Insider reached out to OpenAI for comment. Kevin Weil, the chief product officer at OpenAI, expressed support for Rouch in a reply to her thread. "We love you @kate_rouch!" he wrote. "Proud of you for telling your story and for being so full of fight."

H.C. Wainwright Reiterates Buy Rating on Immix Biopharma (IMMX) Following Promising Interim Results from NXC-201 Trial
H.C. Wainwright Reiterates Buy Rating on Immix Biopharma (IMMX) Following Promising Interim Results from NXC-201 Trial

Yahoo

time23 minutes ago

  • Yahoo

H.C. Wainwright Reiterates Buy Rating on Immix Biopharma (IMMX) Following Promising Interim Results from NXC-201 Trial

On June 4, analyst Robert Burns of H.C. Wainwright reiterated a Buy rating on Immix Biopharma, Inc. (NASDAQ:IMMX) with a price target of $7.00. The analyst based the rating on the promising interim results from the NEXICART-2 Phase 1/2 clinical trial of NXC-201, presented at the 2025 American Society of Clinical Oncology Annual Meeting (ASCO 2025) in Chicago, Illinois. The trial assessed the efficacy of NXC-201 in patients with relapsed/refractory AL amyloidosis and delivered a 100% response rate, with a considerable portion attaining a complete hematologic response. The analyst reasoned that the absence of hematologic relapse or progression and the rapid mean time to response further highlight NXC-201's potential as a viable treatment. A doctor in a white coat discussing clinical trial results with a patient in an oncology practice. Burns also reasoned that NXC-201 appears to have a favorable safety profile, as no patients experienced severe cytokine release syndrome or neurotoxicity. While he highlighted the need for longer-term follow-up and the small sample size, the analyst stated that the interim results are promising when compared to existing treatments. This condition does not have FDA-approved agents, and there exists a fragmented treatment landscape post-frontline therapy, factors that suggest the notable market opportunity for NXC-201 and support the buy rating for Immix Biopharma, Inc. (NASDAQ:IMMX). Immix Biopharma, Inc. (NASDAQ:IMMX) is a biopharmaceutical company that develops therapies for inflammatory diseases and cancer. While we acknowledge the potential of IMMX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Sign in to access your portfolio

Jefferies Maintains Buy Rating on Rhythm Pharmaceuticals (RYTM), Sets $80 Price Target
Jefferies Maintains Buy Rating on Rhythm Pharmaceuticals (RYTM), Sets $80 Price Target

Yahoo

time23 minutes ago

  • Yahoo

Jefferies Maintains Buy Rating on Rhythm Pharmaceuticals (RYTM), Sets $80 Price Target

In a report released on June 4, Dennis Ding from Jefferies maintained a Buy rating on Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) with a price target of $80.00. The analyst based the rating on the company's strategic developments and promising pipeline. One of the primary reasons behind the rating was the anticipated Phase II data for the oral treatment for hypothalamic obesity (HO). It is expected to deliver notable BMI reduction and has been de-risked, thereby extending the potential of the franchise beyond the current expiration dates. A scientist conducting research in a laboratory, studying a Petri dish with advanced biopharmaceuticals. The analyst stated that management is confident in the weekly subcutaneous (subQ) treatment, which closely aligns with the previously approved setmelanotide, and thus further adds to the positive outlook for Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM). According to Ding, the setmelanotide Phase II open-label trial for Prader-Willi Syndrome can also pave the way for a significant opportunity if successful, even after its previous challenges. Management is focusing on patient starts instead of the immediate revenue post-launch, and this strategy supports the long-term growth prospects, according to the analyst. Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) is a commercial-stage biopharmaceutical company that develops and commercializes therapeutics for the treatment of rare diseases. Its product pipeline includes IMCIVREE (setmelanotide), a precision medicine that treats hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. The company also has other programs, including a preclinical suite of investigational candidates to treat congenital hyperinsulinism and a clinical development program for setmelanotide in other rare MC4R pathway diseases. While we acknowledge the potential of RYTM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store